Chemoprevention of carcinogen-induced mammary tumorigenesis by the hybrid polar cytodifferentiation agent, suberanilohydroxamic acid (SAHA)

Anticancer Research

Volumn 19, Issue 6 B, 1999, Pages 4999-5005

  Cohen, Leonard A ^a   Amin, Shantu ^a   Marks, Paul A ^b   Rifkind, Richard A ^b   Desai, Dhimant ^a   Richon, Victoria M ^b  

^a AMERICAN HEALTH FOUNDATION   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Hexamethylene bis acetamide (HMBA); Histone deacetylase (HDAC) inhibitor; Mammary tumor; N methylnitrosourea (NMU); Suberanilo hydroxamic acid (SAHA)

Indexed keywords

CARCINOGEN; HEXAMETHYLENEBISACETAMIDE; HYDROXAMIC ACID DERIVATIVE; METHYLNITROSOUREA; SUBERANILOHYDROXAMIC ACID; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER INCIDENCE; CONTROLLED STUDY; FEMALE; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR VOLUME; WEIGHT GAIN;

ACETAMIDES; ANIMALS; ANTICARCINOGENIC AGENTS; CARCINOGENS; CELL DIFFERENTIATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HYDROXAMIC ACIDS; MAMMARY NEOPLASMS, EXPERIMENTAL; METHYLNITROSOUREA; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0033367018     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Marks PA and Rifkind RA: Erythroleukemic differentiation. Ann Rev Biochem 47: 419-448, 1978.
2. Michaeli J, Rifkind RA, Marks PA: Differentiating agents in cancer therapy. In: Cancer Chemotherapy and Biological Response Modifiers Annual 13, (HM Pinedo, DL Longo, BA Chabner, eds). Elsevier Science Publishers, BV, 1992, pp 286-307.
3. Beere HM and Hickman JA: Differentiation: A suitable strategy for cancer chemotherapy. Anti-cancer Drug Design 8(4): 299-322, 1993.
4. Borken EC, Lotan R, Levens D, Young CW and Waxman S: Differentiation therapy of cancer: Laboratory and Clinical Investigations. Cancer Res 53: 4109-4115, 1993.
5. Hofmann SL: Southwestern Internal Medicine Conference: Retinoids - "Differentiation agents" for cancer treatment and prevention. Amer J Med Sci 304: 202-213, 1992.
6. Parkinson DR, Smith MA, Cheson, BD, Atevenson, HC, and Friedman MA: Trans-retinoic acid and related differentiation agents. Seminar in Oncol 19: 734-741, 1992.
7. Warrell RP Jr, Frankel SR, Miller WH Jr, Scheinberg DA, Itri LM, Hittelman WN, Vayas R, Andreeff M, Tafuri A and Jakubowski A et al: Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). New Eng J Med 324: 1384-1393, 1991.
8. Adamson PC: Clinical and pharmacokinetic studies of All-trans-retinoic acid in pediatric patients with cancer. Leukemia 8 (suppl 3): S22-25, 1994.
9. Muindi JRF, Frankel SR, Huselton C, DeGrazia F, Garland WA, Young CW, Warrell RP Jr: Clinical pharmacology of oral all-trans retinoic acid in patients with acute promyelocytic leukemia. Cancer Res 52: 2138-2142, 1992.
10. Degos L, Dombret H, Chomienne C, Daniel MT, Miclea JM, Chastang C, Castaigne S and Fenaux P: All trans-retinoic acid as a differentiation therapy for acute promyeiocytic leukemia. Blood 85(10): 2643-2653, 1996.
11. Jones PA, Taylor SM: Cellular differentiation, cytidine analogs and DNA methylation. Cell 20: 85-93, 1980.
12. Samid D, Shack S, Myers CB: Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate. J Clin Invest 91: 2288-2295, 1993.
13. Liau MC, Liau CP and Burzynski SR: Potentiation of induced terminal differentiation by phenylacetic acid and related chemicals. Internat J Exptl Clin Chemother 5: 9-17, 1992.
14. Ebert PS, Malinin GI: Induction of erythroid differentiation in Friend murine erythroletikemia cells by inorganic selenium compounds. Biochem Biophys Res Commun 86: 340-349, 1979.
15. Cox R and Goorha S: A study of the mechanism of selenite-induced hypomethylated DNA and differentiation of Friend erythroleukemia cells. Carcinogenesis 7: 2015-2018, 1986.
16. Manolagas SC: Vitamin D and its relevance to cancer. Anticancer Res 7: 625-638, 1987.
17. Chun HG, Leyland-Jones B, Hoth D, Shoemaker D, Wolpert-DeFilippes M, Grieshaber C, Cradock J, Davignon P, Moon R, Rifkind R, Wittes RE: Hexamethylene bisacetamicle: a polar-planar compound entering clinical trials as a differentiating agent. Cancer Treat Reports 70: 991-996, 1986.
18. Young CW, Fanucchi MP, Walsh TD, Baltzer L, Yaldaei S, Stevens Y-W, Gordon C, Tong W, Rifkind RA, Marks PA: Phase I trial and clinical pharmacological evaluation of hexamethylene bisacetamide administration by ten-day continuous intravenous infusion at twenty-eight day intervals. Cancer Res 48: 7304-7309, 1988.
19. Andreeff M, Stone R, Michaeli J, Young CW, Tong WP, Sogoloff H, Ervin T, Kufe D, Rifkind RA, Marks PA: Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agent. Blood 80: 2604-2609, 1992.
20. Marks PA, Breslow R, Rifkind RA, Ngo L, Singh R: Polar/apolar chemical inducers of differentiation of transformed cells: Strategies to improve therapeutic potential. Proc Natl Acad Sci USA 86: 6358-6362, 1989.
21. Breslow R, Jursic B, Fa Yan Z, Friedman E, Leng L, Ngo L, Rifkind RA, Marks PA: Potent cytodifferentiating agents related to hexamethylenebisacetamide. Proc Natl Acad Sci USA 88: 5542-5546, 1991.
22. Richon VM, Emiliani S, Verdin E, Webb Y, Breslow R, Rifkind RA and Marks PA: A class of hybrid polar inducers of transformed cell differentiation are potent inhibitors of histone deacetylases. Proc Natl Acad Sci USA 95: 3003-3007, 1998.
23. Grunstein M: Histone acetylation in chromatin structure and transcription. Nature 389: 349-352, 1997.
24. Strubl K: Histone acetylation and transcriptional regulatory mechanisms. Genes & Development 12: 599-606, 1998.
25. US Department of Health, Education and Welfare. Guidelines for carcinogen bioassay in small rodents. DHEW Publ No. (NIH)76-801, Washington (DC): US Govt Print Off. 1976: 1-65.
26. Chan PC, Head JF, Cohen LA, Wynder EL: Influence of dietary fat on the induction of mammary tumors by N-nitrosomethylurea: associated hormone changes and differences between Sprague-Dawley and F344 rats. J Natl Cancer Inst 59: 1279-83, 1997.
27. Stowell JC, Huot RI and Van Voust L: The synthesis of N-hydroxy-Hl-phenyloctanediamide and its inhibitory effect on proliferation of AXC prostate cancer cells. J Med Chem 381: 1411-1413, 1995.
28. Young S and Hallowes RC, In: Turosov, VX (ed), Pathology of tumors in laboratory animals, Lyons; IARC Sci Pub 5: 31-73, 1973.
29. Russo J, Russo IH, Rogers AE, van Zwietan MJ, Gusterson B: Pathology of tumours in laboratory animals. Tumors of the rat. Tumour of the mammary gland. IARC Sci Publ 99: 47-78, 1990.
30. Kaplan EL and Meier P: Nonparametric estimation from incomplete observation. J Am Stat Assoc 53: 457-481, 1988.
31. Helwig JT, Council KA (eds) Statistical Analysis System User£s Guide, Raleigh, NC, (1979), SAS Institute, pps 245-265.
32. Fleiss JL: Statistical Methods for Rates and Proportions, Second edition. NY: Wiley, P 145-146, 1981,
33. Mantel N and Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. JNCI 22: 719-748, 1959.
34. Fleiss JL: The design and analysis of clinical experiments. NY; Wiley, p 220-240, 1986.
35. Monthly Report on HMBA (hexamethylene bisacetamide; NSC-95580) Drug Eval Branch, NCI. February 29, 1984.
36. Bertram JS, Kolonel LN, Meyskens FL: Rationale and strategies for chemoprevention of cancer in humans. Cancer Res 47: 3012-3031, 1987.
37. El-Bayoumy K: Evaluation of chemopreventive agents against breast cancer and proposed strategies for future clinical trials. Carcinogenesis 25: 2395-2470, 1994.
38. Lippman SM, Kessler JF, Meyskens FL Jr: Retinoids as preventive and therapeutic anticancer agents (part 1) Cancer Treat Reports 71: 391-405, 1987.
39. Lippman SM, Kessler JF, Meyskens FL Jr: Retinoids as preventive and therapeutic anticancer agents (part 2) Cancer Treat Reports 71: 493-515, 1987.
40. Moon RC and Constantinou AI: Dietary retinoids and carotenoids in rodent models of mammary tumorigenesis. Breast Cancer Res and Treat 46: 181-189, 1997.
41. Jeppesen P: Histone acetylation: a possible mechanism for the inheritance of cell memory at mitosis. BioEssays 19: 67-74, 1997.
42. Wolffe AP, Wong J, Pruss D: Activators and repressors: making use of chromatin to regulate transcription. Genes to Cells 2: 291-302, 1997.
43. Sowa Y, Orita T, Minamikawa S, Nakano K, Mizuno T, Nomura H and Sakai T: Histone Deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites. Biochem Biophys Res Commun 241: 142-150, 1997.